FEMY (Femasys) Short-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FEMY Femasys Inc FEMY
56 GF Score
Price $2.95
GF Value $12.09
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Femasys Short-Term Debt?

Femasys FEMY -3.28% 56 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates FEMY with a GF Score™ of 56/100 and a GF Value™ of $12.09 (Possible Value Trap). The stock has 7 warning signs investors should review.

Femasys's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Femasys's quarterly Short-Term Debt declined from Sep. 2025 ($6.78 Mil) to Dec. 2025 ($0.00 Mil) but then stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Femasys's annual Short-Term Debt increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($5.41 Mil) but then declined from Dec. 2024 ($5.41 Mil) to Dec. 2025 ($0.00 Mil).

Femasys Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Femasys Short-Term Debt Related Terms

Femasys Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Femasys's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Femasys Short-Term Debt Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.20 0.14 0.00 5.41 0.00

Femasys Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.76 6.08 6.78 0.00 0.00
FEMY
56GF Score
Femasys Inc FEMY
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Femasys (FEMY) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Femasys' Short-Term Debt too high?
Femasys' current Short-Term Debt is $0.00 Mil. Overall, Femasys has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' Short-Term Debt compare to UEEC and BNGO?
Femasys' Short-Term Debt of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Femasys's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.09, compared to a current price of $2.95 — trading 75.6% below its estimated fair value. The current Short-Term Debt is $0.00 Mil. Femasys' overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Femasys (FEMY), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Femasys (FEMY) Overvalued in 2026?

Based on GuruFocus' analysis, Femasys stock appears to be undervalued. The current stock price of $2.95 is trading 75.6% below its estimated GF Value™ of $12.09. GuruFocus considers Femasys to be Possible Value Trap.

Key valuation signals for FEMY:

  • Short-Term Debt: $0.00 Mil
  • GF Value™: $12.09 vs. price of $2.95 (75.6% below fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Femasys Business Description

Address 3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
56GF Score

Get the complete analysis for FEMY

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.95
Price
$12.09
GF Value